Loera-Torres MA, Guzmán BJ, Ramos E, Jiménez E, Noyola HF

Idioma: Español
Referencias bibliográficas: 22
Paginas: 79-81
Archivo PDF: 61.84 Kb.

FRAGMENTO

Introducción

El cáncer de colon es una de las patologías oncológicas más frecuentes en el mundo. Es la cuarta causa de muerte,1 y origina aproximadamente 150,000 muertes por año. Veinticinco a 55% de los pacientes con cáncer colorrectal desarrollan metástasis hepáticas. De las que 15 a 25% son sincrónicas y un 20 a 25% son metacrónicas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. International Agency for Research on Cancer (IARC), 2012. http://globocan.iarc.fr/factsheet.asp. Accessed 23 Jan 2012

2. Slesser A, Georgiu P, Brown G, et al. The tumor biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis 2012. [Epub ahead of print]

3. Weiss M, D’Angelica M. Patient selection for hepatic resection for metastasic colorectal cancer. J Gastrointest Oncol 2012; 3: 3-10.

4. Tsoulfas G, Pramateftakis G, et al. Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol 2011; 3: 1-9.

5. Pawlik TM, et al. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11: 1057-1077.

6. Pawlik T, Schulick, Choti M. Expanding criteria for resectability of colorectal liver metastases. The Oncologist 2008; 13: 51-64.

7. Ekberg H, Tranberg KG, Andersson R, et al. Determinants o survival in liver resection for colorectal secondaries. Br J Surg 1986; 73: 727-731.

8. Guo XC, San JC. Multi-modality treatment of colorectal liver metastases. World J Gastroenterol 2012; 18: 16-24.

9. Charnsangavej C, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol 2006; 13: 1261-1268.

10. Poultsides G, Schulick R, Pawlik T. Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome. HPB 2010; 12: 43-49.

11. Muratore A, et al. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol 2010; 17: 1324-1329.

12. Konopke R, et al. Resection of colorectal liver metastases: is a resection margin of 3 mm enough?. World J Surg 2008; 32: 2047-2056.

13. Inoue Y, et al. Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer. J Gastrointest Surg 2012; 16: 1171-1180.

14. Pulitanò C, Bodingbauer M, Pawlik T, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institucional analysis. Ann Surg Oncol 2011; 18: 1380-1388.

15. Yoshimi F, et al. Long-term survival after repeat resections of metastases in liver, lung and stomach from sigmoid colon cancer: report of a case. Surg Today 2007; 37: 53-60.

16. Jong MC, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009; 13: 2141–2151.

17. Yun-Zi, et al. Radiofrequency ablation versus hepatic resection for solitary colorectal liver metastases: a meta-analysis. World J Gastroenterol 2011; 17: 4143-4148.

18. Abdalla EK, et al. Resection of hepatic colorectal metastases involving the caudate lobe: perioperative outcome and survival. J Gastrointest Surg 2007; 11: 66-72.

19. McKay A, Fradette K, et al. Long term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surgery 2009; 17: 1-9.

20. Toyama Y. Passibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. World J Surg Oncol 2012; 10: 129.

21. Van der Wal GE, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases. the liver as a permissive soil. Ann Surg 2012; 255: 86-94.

22. Schimanski, et al. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases a randomized, placebo-controlled, multicenter, multinational, doubleblinded phase II trial. BMC Cancer 2012; 12: 144.